AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: March 3, 2025

Language: Английский

---

Factors driving persistence to first-line advanced therapies in inflammatory bowel disease: a real-world study from a tertiary referral centre

Internal and Emergency Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 25, 2025

Abstract Factors driving the persistence of advanced therapies—defined as duration from therapy initiation to discontinuation—in inflammatory bowel disease (IBD) remain unclear. This study aimed evaluate biologics and oral small molecules in a real-word IBD cohort identify influencing factors. Data patients starting at tertiary referral centre after 2010 were retrospectively collected, including discontinuation reasons. Differences probability among therapies analysed, factors versus due failure assessed by univariate multivariate analyses. Among 274 included [median age 42.5 years; F/M 119/155; 146 with Crohn’s (CD) 128 ulcerative colitis; median follow-up 38 months (IQR 14–75)], 141 (51.5%) remained persistent first-line therapy, while 70 (26%) discontinued failure. No significant difference was observed drugs ( p = 0.11). Univariate analysis identified CD phenotype < 0.01), prior concomitant mesalamine or steroids optimisation 0.01) persistence. Multivariate confirmed associated higher persistence, linked increased risk. better drug correlated rate. Targeting deep healing enhancing timely, precise strategies is essential for improving treatment outcomes. Graphical abstract

Language: Английский

---

Fast versus slow fibrosers: Risk factors for fibrosis progression in eosinophilic oesophagitis

European Journal of Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

---